#generic drugs
5 stories
Novartis and Eli Lilly Oppose India Breast Cancer Drug Price Cut Bid
Novartis and Eli Lilly oppose Kerala HC's bid to lower breast cancer drug prices in India, citing high global sales versus minimal local revenue.
The Economic Times · 1m
Antidepressants: Too Many or Progress?
SSRIs prescribed for everyday stress in India may be overused, but access to affordable generics shows mental health progress.
Financialexpress · 1m
Pharma's patent pile-up keeps drug prices high
Drug makers are filing far more patents on minor tweaks to medicines, delaying cheaper generics and extending monopoly pricing without real innovation.
Ars Technica · 1m
Amneal jumps 6.4% on Barclays upgrade
Barclays raises its price target on the drugmaker by 25%, signaling confidence in the company's near-term prospects.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
India eases drug approval rules for generic manufacturers
New regulations will speed up bioequivalence studies and cut import licence processing times in half.
The Economic Times · 1m